Bone, inflammation, and inflammatory bowel disease

被引：56

作者：

Agrawal M. ^{[1
]}

Arora S. ^{[2
]}

Li J. ^{[1
]}

Rahmani R. ^{[1
]}

Sun L. ^{[3
]}

Steinlauf A.F. ^{[4
]}

Mechanick J.I. ^{[3
]}

Zaidi M. ^{[3
]}

机构：

[1] Department of Gastroenterology, Maimonides Medical Center, Brooklyn, NY 11201

[2] Department of Internal Medicine, Wyckoff Heights Medical Center, Affiliate of Weill Cornell Medical College, Brooklyn, NY

[3] Mount Sinai Bone Program, Department of Medicine, Mount Sinai School of Medicine, New York, NY

[4] Department of Gastroenterology, Mount Sinai School of Medicine, New York, NY

来源：

Current Osteoporosis Reports | 2011年 / 9卷 / 4期

关键词：

Bone; Bone loss; Cytokines; Inflammation; Inflammatory bowel disease; Osteoblast; Osteoclast;

D O I：

10.1007/s11914-011-0077-9

中图分类号：

学科分类号：

摘要：

Osteoporosis is a leading cause of morbidity in patients with inflammatory bowel disease (IBD). Bone loss is an early systemic process and occurs even before clinical disease manifests. Bone disease is attributed to vitamin D deficiency, steroid use, and/or systemic inflammation. In this review, we discuss the molecular pathways of bone loss mediated by inflammatory cytokines and other mediators. Further research will hopefully clarify the mechanisms of inflammation-induced bone loss in IBD and guide effective treatment modalities. © 2011 Springer Science+Business Media, LLC.

引用

页码：251 / 257

页数：6

共 57 条

[1]

Who are candidates for prevention and treatment for osteoporosis?, Osteoporosis International, 7, 1, pp. 1-6, (1997)

[2]

Burge R., Dawson-Hughes B., Solomon D.H., Wong J.B., King A., Tosteson A., Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025, Journal of Bone and Mineral Research, 22, 3, pp. 465-475, (2007)

[3]

Reid I.R., Glucocorticoid osteoporosis - Mechanisms and management, European Journal of Endocrinology, 137, 3, pp. 209-217, (1997)

[4]

Pazianas M., Zaidi M., Subhani J.M., Finch P.J., Ang L., Maxwell J.D., Efferent loop small intestinal vitamin D receptor concentration and bone mineral density after Billroth II (Polya) gastrectomy in humans, Calcified Tissue International, 72, 4, pp. 485-490, (2003)

[5]

Schulte C., Dignass A.U., Mann K., Goebell H., Reduced bone mineral density and unbalanced bone metabolism in patients with inflammatory bowel disease, Inflammatory Bowel Diseases, 4, 4, pp. 268-275, (1998)

[6]

Shen B., Remzi F.H., Oikonomou I.K., Lu H., Lashner B.A., Hammel J.P., Skugor M., Bennett A.E., Brzezinski A., Queener E., Fazio V.W., Risk factors for low bone mass in patients with ulcerative colitis following ileal pouch-anal anastomosis, Am J Gastroenterol, 104, 3, pp. 639-46, (2009)

[7]

Tignor A.S., Wu B.U., Whitlock T.L., Lopez R., Repas K., Banks P.A., Conwell D., High prevalence of low-trauma fracture in chronic pancreatitis, Am J Gastroenterol, 105, 12, pp. 2680-6, (2010)

[8]

Ward L.M., Rauch F., Matzinger M.A., Benchimol E.I., Boland M., MacK D.R., Iliac bone histomorphometry in children with newly diagnosed inflammatory bowel disease, Osteoporos Int, 21, pp. 331-337, (2010)

[9]

Turner J., Pellerin G., Mager D., Prevalence of metabolic bone disease in children with celiac disease is independent of symptoms at diagnosis, J Pediatr Gastroenterol Nutr, 49, 5, pp. 589-93, (2009)

[10]

Oostlander A.E., Et al., Dutch Initiative on Crohn and Colitis (ICC). Histomorphometric analysis reveals reduced bone mass and bone formation in patients with quiescent Crohn's disease, Gastroenterology, 140, 1, pp. 116-23, (2011)

← 1 2 3 4 5 6 →